ORSYTHIA COMPONENT ETHINYL ESTRADIOL
Partial Epilepsy
Bial - Portela C S.A.Small moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Partial Epilepsy cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Eslicarbazepine Acetate Sumitomo Pharma America, Inc. | Phase 4 | A |
Cenobamate Ono Pharmaceutical Co., Ltd. | Phase 4 | BBB |
Xcopri SK Life Science, Inc. | Phase 3 | BB |
Oxcarbamezapine Supernus Pharmaceuticals, Inc. | Phase 3 | BB |
BELNACASAN Vertex Pharmaceuticals Incorporated | Phase 2 | B |
View all 10 →
Same molecule, other indications
ORSYTHIA COMPONENT ETHINYL ESTRADIOL is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →